A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC
A phase 1/2 trial of 161Tb RAD402 in prostate cancer, run by Radiopharm Theranostics, Ltd, now recruiting.
Overview
A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC is a phase 1/2 interventional study registered as NCT07259213 by Radiopharm Theranostics, Ltd, with 73 participants planned, started 2026-03-05 and due to reach its primary completion in 2028-11-30. Interventions recorded: 161Tb RAD402.
Similar pages
not linked directly; found by shared links- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Radiopharm Theranostics, Prostate cancer and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Radiopharm Theranostics and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares Prostate cancer and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares Prostate cancer and the tag pipeline.
- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares Prostate cancer and the tag pipeline.